These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 22988347

  • 1. Update of faecal markers of inflammation in children with cystic fibrosis.
    Lee JM, Leach ST, Katz T, Day AS, Jaffe A, Ooi CY.
    Mediators Inflamm; 2012; 2012():948367. PubMed ID: 22988347
    [Abstract] [Full Text] [Related]

  • 2. Intestinal inflammation and impact on growth in children with cystic fibrosis.
    Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee JM, Strachan R, Day AS, Jaffe A, Ooi CY.
    J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):521-6. PubMed ID: 25539196
    [Abstract] [Full Text] [Related]

  • 3. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA, Leach ST, Day AS.
    Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
    [Abstract] [Full Text] [Related]

  • 4. Evidence for a Cystic Fibrosis Enteropathy.
    Adriaanse MP, van der Sande LJ, van den Neucker AM, Menheere PP, Dompeling E, Buurman WA, Vreugdenhil AC.
    PLoS One; 2015 Mar; 10(10):e0138062. PubMed ID: 26484665
    [Abstract] [Full Text] [Related]

  • 5. Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?
    Ooi CY, Pang T, Leach ST, Katz T, Day AS, Jaffe A.
    Dig Dis Sci; 2015 Oct; 60(10):2946-52. PubMed ID: 26271615
    [Abstract] [Full Text] [Related]

  • 6. Serum Level of D-Lactate in Patients with Cystic Fibrosis: Preliminary Data.
    Więcek S, Chudek J, Woś H, Bożentowicz-Wikarek M, Kordys-Darmolinska B, Grzybowska-Chlebowczyk U.
    Dis Markers; 2018 Oct; 2018():5940893. PubMed ID: 30116405
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term evaluation of faecal calprotectin levels in a European cohort of children with cystic fibrosis.
    Roca M, Masip E, Colombo C, Boon M, Hulst JM, Garriga M, de Koning BAE, Bulfamante A, de Boeck K, Ribes-Koninckx C, Calvo-Lerma J.
    Arch Dis Child; 2024 Jun 19; 109(7):552-556. PubMed ID: 38123920
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Severe disease in Cystic Fibrosis and fecal calprotectin levels.
    Parisi GF, Papale M, Rotolo N, Aloisio D, Tardino L, Scuderi MG, Di Benedetto V, Nenna R, Midulla F, Leonardi S.
    Immunobiology; 2017 Mar 19; 222(3):582-586. PubMed ID: 28012584
    [Abstract] [Full Text] [Related]

  • 12. Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis.
    Lisowska A, Madry E, Pogorzelski A, Szydłowski J, Radzikowski A, Walkowiak J.
    Scand J Clin Lab Invest; 2010 Sep 19; 70(5):322-6. PubMed ID: 20560844
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial.
    López-Neyra A, Suárez L, Muñoz M, de Blas A, Ruiz de Valbuena M, Garriga M, Calvo J, Ribes C, Girón Moreno R, Máiz L, González D, Bousoño C, Manzanares J, Pastor Ó, Martínez-Botas J, Del Campo R, Cantón R, Roy G, Menacho M, Arroyo D, Zamora J, Soriano JB, Lamas A.
    Prostaglandins Leukot Essent Fatty Acids; 2020 Nov 19; 162():102186. PubMed ID: 33038833
    [Abstract] [Full Text] [Related]

  • 15. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis.
    Østgård RD, Deleuran BW, Dam MY, Hansen IT, Jurik AG, Glerup H.
    Scand J Rheumatol; 2018 Jan 19; 47(1):48-55. PubMed ID: 28649913
    [Abstract] [Full Text] [Related]

  • 16. Surrogate Markers of Intestinal Inflammation in Paediatric Patients with Inflammatory Bowel Disease.
    Shentova R, Baycheva M, Kofinova D, Hadjiiski P, Yaneva P.
    Folia Med (Plovdiv); 2020 Jun 30; 62(2):271-275. PubMed ID: 32666743
    [Abstract] [Full Text] [Related]

  • 17. Fecal Calprotectin in Cystic Fibrosis and Its Relation to Disease Parameters: A Longitudinal Analysis for 12 Years.
    Ellemunter H, Engelhardt A, Schüller K, Steinkamp G.
    J Pediatr Gastroenterol Nutr; 2017 Oct 30; 65(4):438-442. PubMed ID: 28207476
    [Abstract] [Full Text] [Related]

  • 18. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G, Garnero P, Moussata D, Cuerq C, Préaudat C, Duclaux-Loras R, Mialon A, Drai J, Flourié B, Nancey S.
    Inflamm Bowel Dis; 2015 Feb 30; 21(2):331-6. PubMed ID: 25625487
    [Abstract] [Full Text] [Related]

  • 19. Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children.
    Garg M, Leach ST, Coffey MJ, Katz T, Strachan R, Pang T, Needham B, Lui K, Ali F, Day AS, Appleton L, Moeeni V, Jaffe A, Ooi CY.
    J Cyst Fibros; 2017 Sep 30; 16(5):631-636. PubMed ID: 28416415
    [Abstract] [Full Text] [Related]

  • 20. Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: a clue to the increased risk of intestinal malignancy in adulthood?
    Pang T, Leach ST, Katz T, Jaffe A, Day AS, Ooi CY.
    J Gastroenterol Hepatol; 2015 May 30; 30(5):866-71. PubMed ID: 25376228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.